Innate Pharma Highlights Phase 1/2 Safety, Preliminary Efficacy Of SAR'579/IPH6101 For Relapsed/Refractory Acute Myeloid Leukemia; SAR'579, In Development By Sanofi, Was Well Tolerated Up To Doses Of 3 Mg/Kg QW With Observed Clinical Benefit
Portfolio Pulse from Benzinga Newsdesk
Innate Pharma announced positive Phase 1/2 safety and preliminary efficacy results for SAR'579/IPH6101, a drug for relapsed/refractory acute myeloid leukemia. The drug, developed by Sanofi, was well tolerated up to doses of 3 mg/kg QW with observed clinical benefits.
May 26, 2023 | 7:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Innate Pharma's positive Phase 1/2 results for SAR'579/IPH6101 may boost investor confidence in the company's drug development capabilities.
The positive results indicate that Innate Pharma's drug development is progressing well, which may lead to increased investor confidence and a potential short-term increase in stock price.
CONFIDENCE 80
IMPORTANCE 65
RELEVANCE 70
POSITIVE IMPACT
Sanofi's involvement in the development of SAR'579/IPH6101 may positively impact its stock price as the drug shows promising results in Phase 1/2 trials.
As Sanofi is involved in the development of the drug, the positive results may lead to increased investor confidence in the company's drug development capabilities, potentially resulting in a short-term increase in stock price.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 30